<DOC>
	<DOCNO>NCT00913939</DOCNO>
	<brief_summary>This pilot study initiate research program test early technical clinical performance novel procedure MRI-guided high-dose-rate ( HDR ) prostate brachytherapy . Testing proceed two cohort patient . In Arm 1 , patient locally recurrent prostate cancer radiotherapy receive tumor-targeted salvage HDR brachytherapy . Arm 1 study coordinate closely integrated separate concurrent study MRI-guided prostate biopsy , perform prior accrual Arm 1 trial ( UHN 05-0641-C ) . In arm 2 , patient locally advanced prostate cancer receive boost prostate-targeted HDR brachytherapy external beam radiotherapy . This technique prospectively evaluate 100 patient . Preliminary data acquire pilot study determine technical limit MRI guide HDR brachytherapy critical judicious conduct subsequent phase II clinical trial . This proposal innovative two fundamental way : MRI-guidance , specific tumor target HDR brachytherapy . Successful completion study individualize local therapy , benefit proportion cancer patient initial radiotherapeutic intervention fail , also provide valuable technical clinical validation novel image-guided ( IG ) approach clinically feasible could apply broadly prostate cancer therapy .</brief_summary>
	<brief_title>High-Dose-Rate Brachytherapy</brief_title>
	<detailed_description>Two hundred nineteen thousand new case prostate cancer project Unites States 2007 , external beam radiotherapy ( EBRT ) constitute mainstay local therapy increase proportion newly diagnose patient . Despite improvement delivery reduction associate toxicity external beam radiotherapy , local persistence recurrence disease remain prevalent 25-51 % patient . Local disease EBRT risk factor subsequent metastatic progression prostate cancer-specific mortality , cause morbidity include hematuria , obstructive uropathy , chronic pain . Given prevalence , lack satisfactory local salvage treatment , fear prostate cancer recurrence show impose substantial burden suffering patient . Stereotactic needle placement MRI-guidance enable two critical step tumor-targeted brachytherapy : 1 ) directly guide brachytherapy catheter sit tumor recurrence , 2 ) permit treatment plan delivery base 3D MRI image . MRI-based HDR brachytherapy precisely identify location brachytherapy catheter relative target volume adjacent normal structure risk radiation injury , obviate need invasive saturation ( 24-100 ) mapping biopsy . This study build evidence support concept MRI-guidance tumor-targeted HDR brachytherapy management prostate cancer . This trial strive demonstrate improvement technical performance MRI-guidance , explore novel paradigm patient-specific modulation dose intensity base region tumor burden .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Prior enrollment UHN 050641C UHN 125015C ( Arm 1 ) Histological evidence recurrent prostate adenocarcinoma ( Arm 1 ) PSA double time &gt; 6 month ( Arm 1 ) Highrisk localize prostate cancer ( &gt; T2 G &gt; 7 PSA &gt; 20 ) ( Arm 2 ) Planned EBRT + HDR boost ( +/ hormone therapy ) ( Arm 2 ) ECOG 0 1 Age &gt; 18 year Informed consent : All patient must sign document inform consent indicate understanding investigational nature risk study protocol relate study perform . Radiological evidence regional distant metastasis Contraindications MRI ( Patient weigh &gt; 136kg ( scanner weight limit ) , Patients pacemaker , cerebral aneurysm clip , shrapnel injury , implantable electronic device compatible MRI ) Bleeding diathesis anticoagulative therapy temporarily cease brachytherapy Previous prostate brachytherapy Active hormonal therapy ( Arm 1 ) &gt; 50 % contiguous sextant involve tumor ( Arm 1 ) Previous pelvic radiotherapy ( Arm 2 ) Contraindications endorectal coil , surgically absent rectum , severe hemorrhoid colorectal surgery . Latex Allergy Contraindications conscious sedation , local anesthesia , spinal/epidural anesthesia . IPSS &gt; 18 Large TURP defect TURP within past 6 month Prostate gland size &gt; 80cc History Ulcerative Colitis , Crohn 's Disease , Ataxia Telangiectasia , SLE Other medical condition deem PI make patient ineligible MRIguided Prostate HDR brachytherapy .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>HDR Brachytherapy</keyword>
	<keyword>Prostate Brachytherapy</keyword>
</DOC>